La 24e édition du Congrès de Pneumologie de Langue Française - 24e CPLF aura lieu du vendredi 24 au dimanche 26 janvier 2020 au Parc des expositions de Paris - Porte de Versailles, Hall 7.3
Les Thèmes principaux abordés seront : Asthme et allergie - Médecine prédictive, de précision et personnalisée.
Découvrez à cette occasion nos deux revues dans cette spécialité - Retrouvez nous sur le stand 64 du congrès
Découvrez un article de la revue sur Nouvelle approche thérapeutique dans l’asthme : l’immunothérapie peptidique
La nouvelle revue en anglais de la Société de pneumologie de langue française !
Découvrez ici l'éditorial de la revue
In the globalized and competitive international context (both in terms of research and scientific journals), it appeared important to ensure the international presence of French pulmonology by publishing a medical journal of the Société de pneumologie de langue française (SPLF) in English. The decision by the SPLF authorities to propose such a journal followed a period of several years of “bilingualism” by the Revue des Maladies Respiratoires (another journal edited in French by the SPLF), during which a selection of articles was translated and indexed in English. Experience has shown that this option did not fully meet its objective in terms of international visibility.
Respiratory Medicine and Research, the new English-language journal of the SPLF, has been launched in early 2019. This English-language “RMR” will be complementary to the French-language “RMR” (Revue des Maladies Respiratoires), which will of course continue to exist. These two journals will be independent: the French-language RMR will continue its important international publication in French, while the English-language RMR will be the international English-language journal of the SPLF. The SPLF, with these two scientific communication tools, will thus fully assume its international vocation: the French-speaking “exception” will be echoed by the English language among non-French speaking scientists.
In order to ensure the rapid start of this new journal, and its indexing by Pubmed and Clarivate Analytics (which produces the“impact factors”), this English-language RMR takes over from the Revue de Pneumologie Clinique, the last issue of which has been published in December 2018. Respiratory Medicine and Researchis available in the form of an exclusively online journal, available on subscription, and published by the Elsevier group. The Revue de Pneumologie Clinique was owned by the Elsevier group, while Respiratory Medicine and Research will be an Elsevier (50%) – Société de pneumologie de langue française joint venture (50%).
Respiratory Medicine and Research aims at publishing original articles, literature reviews, clinical cases (only if they are innovative in understanding a medical problem), recommendations for good practice (including those of SPLF) and texts from task forces or dedicated working groups, as well as editorials and correspondence. All aspects of respiratory medicine will be addressed: clinical, basic and translational research are welcome. The contents will be specific to each of the journals, as the new journal is not a translation of the French RMR. Respiratory Medicine and Research has an autonomous editorial board, coordinated with that of the Revue des Maladies Respiratoires, and composed of pulmonologists, pediatricians, and researchers. It will be able to approach all the issues of the discipline in a balanced way.
The editorial project is ambitious and of major importance for French pulmonology! The success of this initiative will obviously depend on the mobilization of all, to offer quality content that reflect the dynamism of our discipline.
We look forward to your submissions to this new journal!!!
Disclosure of interest
D. Montani reports grants and personal fees from Actelion, grants and personal fees from Bayer, personal fees from GSK,personal fees from MSD, personal fees from Pfizer, outside the submitted work.
N. Roche: honoraria and/or funds from 3 M, Astra Zeneca,Boehringer Ingelheim, Chiesi, GlaxoSmithKline, MSD,Mundipharma, Novartis, Pfizer, Sandoz, Sanofi, TEVA, Trudell,Zambon.
P. R. Burgel reports personal fees from Astra-Zeneca, grants andpersonal fees from Boeringher Ingelheim, personal fees from Chiesi, personal fees from GSK, personal fees from Novartis, personal fees from Pfizer, personal fees from Teva, personal fees from Vertex, personal fees from Zambon, outside the submitted work.
F.-X. Blanc, B. Pigearias declare that they have no competing interest.
Chief Editor of Respiratory Medicine, Research P.-R. Burgela,∗
Deputy Chief Editor of Respiratory Medicine, Research D. Montanib
Chief Editor of Revue des Maladies Respiratoires F.-X. Blancc
SPLF international affairs B. Pigearias d
SPLF president N. Rochea
a Service de pneumologie, hôpital Cochin, 27, rue du Faubourg St Jacques, 75014 Paris, France
b Service de pneumologie, hôpital Bicêtre, Le Kremlin-Bicêtre, France
c Service de pneumologie, hôpital G. et R. Laënnec, CHU de Nantes, Nantes, France
d Laboratoire du sommeil et de l’effort, France
∗ Corresponding author. E-mail address: firstname.lastname@example.org (P.-R. Burgel)
© 2019 Published by Elsevier Masson SAS.